Lumenis’ UltraPulse TotalFX Treatment Featured on ABCNews 20/20 as a Secret Weapon for Treating for Burn Scars
SANTA CLARA, Calif., July 20 /PRNewswire/ — Lumenis Ltd., the world’s largest medical laser company, announced today that their UltraPulse TotalFX treatment was featured on 20/20 on Friday, July 17(th) 2009, as a “secret weapon” to improve the texture, flexibility and appearance of severe scars from traumatic injuries.
The comprehensive feature chronicled the personal stories of survival of Chandra, Trae and Jordan Berns, who at just 17 months old were burned by a devastating arson fire that claimed the life of their mother. The triplets have lived with the reminder of that horrible night ever since and now, at the age of 22, they have found new hope in Lumenis’ Ultrapulse Laser. After a total of three treatments, by Dr. Jill Waibel using the Ultrapulse, the triplets have all noticed significant reduction in the appearance of scars on their arms, chest, back and face and should continue to see further results in the next few months. In addition to cosmetic improvements, they have experienced improved flexibility and mobility in their arms and other areas of their bodies.
A pioneer in treating burns, Dr. Jill Waibel of the Palm Beach Aesthetic Dermatology & Laser Center in Palm Beach, Florida is very sympathetic to the emotional journey of burn victims and stated, “Scarring can be psychologically traumatic for any patient … bad scars remind the patient over and over about the event that caused the injury.”
Thick, deep, and inflexible, burn scars such as those shared by the Berns triplets are the most difficult skin wounds to treat, and although physicians and scientists have worked for years seeking out new treatment options, including other lasers, nothing has been effective on these severe burn scars until now.
Dr. Waibel’s new “secret weapon” in treating scars is Lumenis’ UltraPulse TotalFX laser. Commonly used for other cosmetic conditions such as deep wrinkles and unwanted pigment, Dr. Waibel discovered that this system could also be used to treat burn scars. The UltraPulse laser uses two different methods of treating the skin as well as a unique delivery to stimulate new collagen growth, lighten dark colors on the scar and remove some of the scar tissue.
“We literally take the scar out, and as a result new collagen is stimulated and formed. We not only improve the scar — we create new healthy skin where there was a scar,” explained Dr. Waibel. “We are able to treat scars that we were never able to treat before.”
“Lumenis is excited to support the triplets’ treatments along with Dr. Waibel’s exciting work in scar revision, but most importantly to provide hope for Chandra, Trae and Jordan where they had no options before,” stated Mr. Dov Ofer, CEO of Lumenis. “The company is grateful for the significant efforts of all of the physicians and nurses at the Palm Beach Aesthetic Dermatology & Laser Center especially that of Dr. Waibel and Dr. Kenneth Beer its founder”.
“The significant improvement in the appearance of the triplets’ scars has generated profound interest in using UltraPulse technology in improving the quality of life for burn survivors around the globe. The treatment offers hope for many since it is far less traumatic than traditional surgical revision of scars, results can be seen within a few weeks and the skin continues to improve for up to six months following treatment,” added Mr. Robert Mann, SVP and General Manager of Lumenis Aesthetic Business.
Motivated to share their success with others, Chandra, Trae and Jordan have also started a foundation to help burn survivors cover the cost of their treatments which is called “Three For Hope” (read more about the Berns Triplets www.bernstriplets.com and the Ultrapulse treatments featured on Lumenis website: www.aesthetic.lumenis.com
Lumenis Ltd., the world’s leading medical laser company is a global developer, manufacturer and seller of laser, light-based and radiofrequency devices for surgical, aesthetic and ophthalmic applications, with more than 800 employees globally. Lumenis has over 250 patents worldwide, over 75 FDA clearances, worldwide presence in over 100 countries, and an installed base of over 70,000 systems. For more information about Lumenis and its products, please go to: www.lumenis.com.
Lumenis((R)) is a registered trademark of Lumenis Ltd.
Contacts: Charly Rok Michelle Maydan Lippe Taylor Director of Corporate Communications Office: 212-598-4400 x155 Lumenis Cell: 917-912-2863 Toll-free: 1-866-569-0597 firstname.lastname@example.org Office: +972-4-959-9004 email@example.com
Certain statements and information in this press release may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections of results of operations or of financial condition and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. Forward-looking statements are often characterized by the use of forward-looking terminology such as “may,” “will,” “expect,” “anticipate,” “estimate,” “continue,” “believe,” “should,” “intend,” “project” or other similar words, but are not the only way these statements are identified. We have based these forward-looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements may be found in our most recent Annual Report on Form 20-F, including the section therein entitled “Risk Factors”, as well in our reports on Form 6-K, filed with the Securities and Exchange Commission.
SOURCE Lumenis Ltd.